Role of positron emission tomography - Computed tomography in head and neck cancer

Annals of Otology, Rhinology and Laryngology

Volumn 120, Issue 9, 2011, Pages 593-602

  Cashman, Emma C ^a   MacMahon, Peter J ^b   Shelly, Martin J ^b   Kavanagh, Eoin C ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Computed tomography; Head and neck cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

EID: 80052604373     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348941112000907     Document Type: Review

References (75)

1. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005;5:127-35.
2. http://www.cancer.net. Accessed January 2011.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Bryce DP, Ireland PE, Rider WD. Experience in the surgical and radiological treatment in 500 cases of carcinoma of the larynx. Ann Otol Rhinol Laryngol 1963;72:416-30.
5. Bryce DP, Rider WD. Pre-operative irradiation in the treatment of advanced laryngeal carcinoma. Laryngoscope 1971;81:1481-90.
6. Parsons JT, Mendenhall WM, Cassisi NJ, Issacs JH Jr, Million RR. Hyperfractionation for head and neck cancer. Int J Radiat Oncol Biol Phys 1988;14:649-58.
7. Schöder H, Yeung HWD. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34:180-97.
8. Kim SY, Roh JL, Yeo NK, et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 2007;18:1698-703.
9. Syed R, Bomanji JB, Nagabhushan N, et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 2005;92:1046-50.
10. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JPA. 18F- flurodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100:712-20.
11. Ferlito A, Rinaldo A, Robbins KT, et al. Changing concepts in the surgical management of the cervical node metastasis. Oral Oncol 2003;39:429-35.
12. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50(suppl 1):74S-88S.
13. Castelijns JA, van den Brekel MW. Imaging of lymphadenopathy in the neck. Eur Radiol 2002;12:727-38.
14. Castelijns JA, van den Brekel MW. Detection of lymph node metastases in the neck: radiologic criteria. AJNR Am J Neuroradiol 2001;22:3-4.
15. Hao SP, Ng SH. Magnetic resonance imaging versus clinical palpation in evaluating cervical metastasis from head and neck cancer. Otolaryngol Head Neck Surg 2000;123:324-7.
16. Stern WB, Silver CE, Zeifer BA, Persky MS, Heller KS. Computed tomography of the clinically negative neck. Head Neck 1990;12:109-13.
17. Feinmesser R, Freeman JL, Feinmesser M, Noyek A, Mullen JB. Role of modern imaging in decision-making for elective neck dissection. Head Neck 1992;14:173-6.
18. Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998;207:123-30.
19. Som PM. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR Am J Roentgenol 1992;158:961-9.
20. O 'Neill JP, Moynagh M, Kavanagh E, O'Dwyer T. Prospective, blinded trial of whole-body magnetic resonance imaging versus computed tomography positron emission tomography in staging primary and recurrent cancer of the head and neck. J Laryngol Otol 2010;124:1274-7.
21. Chua ML, Ong SC, Wee JT, et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck 2009;31:346-54.
22. Ng SH, Chan SC, Yen TC, et al. Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. Eur Radiol 2009;19:2965-76.
23. Yoshida K, Suzuki A, Nagashima T, et al. Staging primary head and neck cancers with (18)F-FDG PET/CT: is intravenous contrast administration really necessary? Eur J Nucl Med Mol Imaging 2009;36:1417-24.
24. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 2009;36:12-22. [Erratum in Eur J Nucl Med Mol Imaging 2009;36:538.]
25. Krabbe CA, Pruim J, van der Laan BF, Rödiger LA, Roodenburg JL. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. Oral Oncol 2009;45:234-40.
26. Ng SH, Chan SC, Liao CT, et al. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology 2008;50:969-79.
27. Gourin CG, Watts TL, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. Laryngoscope 2008;118:671-5.
28. L iu FY, Lin CY, Chang JT, et al. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med 2007;48:1614-9.
29. Veit-Haibach P, Luczak C, Wanke I, et al. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 2007;34:1953-62.
30. Chen YK, Su CT, Ding HJ, et al. Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res 2006;26:1471-7.
31. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001;23:1056-60.
32. Brouwer J, de Bree R, Hoekstra OS, et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient? Laryngoscope 2005; 115:1813-7.
33. Brouwer J, Senft A, de Bree R, et al. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol 2006;42:275-80.
34. Schmid DT, Stoeckli SJ, Bandhauer F, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003;113:888-91.
35. Stokkel MP, Moons KG, ten Broek FW, van Rijk PP, Hordijk GJ. 18F-flurodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 1999;86:2370-7.
36. Jovanovic A, van der Tol IG, Kostense PJ, et al. Second respiratory and upper digestive tract cancer following oral squamous cell carcinoma. Eur J Cancer B Oral Oncol 1994;30B: 225-9.
37. Schwartz LH, Ozsahin M, Zhang GN, et al. Synchronous and metachronous head and neck carcinomas. Cancer 1994;74: 1933-8.
38. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol 2001; 19:1358-62.
39. Adams S, Baum RP, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-60.
40. Pohar S, Brown R, Newman N, Koniarczyk M, Hsu J, Feiglin D. What does PET imaging add to conventional staging of head and neck cancer patients? Int J Radiat Oncol Biol Phys 2007;68:383-7.
41. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. (18)F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol 2011;137:1085-93.
42. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234:879-85.
43. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101:2641-9.
44. Fogarty GB, Peters LJ, Stewart J, Scott C, Rischin D, Hicks RJ. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck 2003;25:138-45.
45. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 1997;22:209-14.
46. L owe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]flurodeoxyglucose positron emission tomography. Head Neck 1997;19:666-74.
47. L onneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol 2010;28:1190-5.
48. L apela M, Grénman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1995;197:205-11.
49. Keller F, Psychogios G, Linke R, et al. Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT. Head Neck (in press).
50. Roh JL, Yeo NK, Kim JS, et al. Utility of 2-[18F] fluoro-2-deoxy-D- glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 2007;43:887-93.
51. Paul SA, Stoeckli SJ, von Schulthess GK, Goerres GW. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary. Eur Arch Otorhinolaryngol 2007; 264:189-95.
52. Heron DE, Andrade RS, Flickinger J, et al. Hybrid PETCT simulation for radiation treatment planning in head-andneck cancers: a brief technical report. Int J Radiat Oncol Biol Phys 2004;60:1419-24.
53. Zimmer LA, Branstetter BF, Nayak JV, Johnson JT. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 2005;115:2029-34.
54. Quon A, Fischbein NJ, McDougall IR, et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 2007;48(suppl 1):58S-67S.
55. Schöder H, Carlson DL, Kraus DH, et al. 18F-FDG PET/ CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755-62.
56. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 2002;24:345-9.
57. Myers LL, Wax MK, Nabi H, Simpson GT, Lamonica D. Positron emission tomography in the evaluation of the N0 neck. Laryngoscope 1998;108:232-6.
58. Agarwal V, Branstetter BF IV, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am 2008;41:23-49, v.
59. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110 (suppl 93):1-18.
60. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047-58.
61. Kunkel M, Förster GJ, Reichert TE, et al. Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 2003;39:170-7.
62. Yen RF, Hong RL, Tzen KY, Pan MH, Chen TH. Wholebody 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med 2005;46:770-4.
63. Yen TC, Lin CY, Wang HM, et al. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;65:1307-14.
64. Kunkel M, Helisch A, Reichert TE, et al. Clinical and prognostic value of [(18)F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy. Oral Oncol 2006;42:297-305.
65. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-andneck cancer - a long-term outcome report. Int J Radiat Oncol Biol Phys 2009;74:9-14.
66. Rabalais AG, Walvekar R, Nuss D, et al. Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. Laryngoscope 2009;119:1120-4.
67. X ie P, Yue JB, Zhao HX, et al. Prognostic value of 18FFDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2010;136:883-9.
68. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers. V.2.2008. Available at: http://www.nncn.org/ professionals/physician-gls/PDF/head-and-neck.pdf. Accessed February 1, 2011.
69. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intraarterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging 2010;37:1318-27.
70. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007;117:2129-34.
71. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005;63:991-9.
72. O ng SC, Schöder H, Lee NY, et al. Clinical utility of 18FFDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49:532-40.
73. Gourin CG, Williams HT, Seabolt WN, Herdman AV, Howington JW, Terris DJ. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006;116:705-10.
74. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2007;133:435-40.
75. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.